All In Biotech

Drug Trial Radar · NCT06816251

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Feb 25, 2025

Primary completion

Nov 18, 2025

Study completion Nov 18, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.

Conditions

  • Non-obstructive Hypertrophic Cardiomyopathy

Interventions

  • HRS-1893Drug

    HRS-1893 tablet.

  • HRS-1893 placeboDrug

    HRS-1893 tablet placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Up to 14 weeks.
  2. The incidence of left ventricular ejection fraction (LVEF) < 50%Time frame: Up to 14 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.